GSK has got the year off to a good start thanks to strong growth from vaccines Shingrix and Arexvy, with the latter expected to gain an expanded US license by mid-2024.
That has instilled a growing sense of momentum at the company, with CEO Emma Walmsley commenting that she "welcomed" competition...